# US 5,770,208 A · Staphylococcus aureus B-linked hexosamine antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,770,208 A
- Document ID: US5770208A
- Status: Granted
- Kind: A
- Application number: 08/712,438
- Filed: 1996-09-11
- Granted: 1998-06-23
- Earliest claimed: 1996-09-11
- Assignees: Nabi
- Inventors: Ali Ibrahim Fattom; Atulkumar Induprasad Patel
- Web page: https://patentgrep.com/patent/US5770208A

## CPC

- G01N 33/56938: {Staphylococcus}
- A61K 39/085: Staphylococcus
- A61P 31/04: Antibacterial agents
- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- Y10S 435/81: Packaged device or kit
- Y10S 435/822: using bacteria or actinomycetales
- Y10S 435/964: including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
- Y10S 435/975: Kit
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A negatively-charged S. aureus antigen contains .beta.-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection.

## Claims

### Claim 1

An isolated Staphylococcus aureus antigen that comprises .beta.-linked hexosamine, wherein said antigen contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy and specifically binds with antibodies to Staphylococcus aureus Type 336 deposited under ATCC 55804.

### Claim 2 (depends on 1)

An antigen-carrier conjugate, comprising an antigen as claimed in claim 1 conjugated to an immunocarrier.

### Claim 3 (depends on 2)

An antigen-carrier conjugate as claimed in claim 2, wherein said immunocarrier is a recombinantly-produced, non-toxic mutant strain of Pseudomonas aeruginosa exotoxin A.

### Claim 4 (depends on 1)

A composition consisting essentially of an antigen as claimed in claim 1, and a sterile, pharmaceutically-acceptable carrier therefor.

### Claim 5 (depends on 2)

A composition consisting essentially of an antigen-immunocarrier conjugate as claimed in claim 2, and a sterile, pharmaceutically-acceptable carrier therefor.

### Claim 6 (depends on 5)

A composition as claimed in claim 5, wherein said immunocarrier is a recombinantly-produced, non-toxic mutant of Pseudomonas aeruginosa exotoxin A.

### Claim 7

A composition comprising:
an isolated S. aureus antigen that comprises .beta.-linked hexosamine, wherein said antigen contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy and specifically binds with antibodies to Staphylococcus aureus Type 336 deposited under ATCC 55804;
S. at least aureus Type 5 polysaccharide antigen or S. aureus Type 8 polysaccharide antigen;
and a sterile pharmaceutically acceptable carrier therefor.

### Claim 8 (depends on 7)

A composition as claimed in claim 7, comprising both said Type 5 and Type 8 polysaccharide antigens.

### Claim 9 (depends on 8)

A composition as claimed in claim 8, wherein each of said antigens is conjugated to an immunocarrier.

### Claim 10 (depends on 9)

A composition as claimed in claim 9, wherein each of said antigens is conjugated to the same immunocarrier.

### Claim 11 (depends on 9)

A composition as claimed in claim 9, wherein said immunocarrier is a recombinantly-produced, non-toxic mutant strain of Pseudomonas aeruginosa exotoxin A.

### Claim 12 (depends on 5)

An immunotherapy method comprising a step of administering to a subject an immunostimulatory amount of a composition as claimed in claim 5.

### Claim 13 (depends on 9)

An immunotherapy method comprising a step of administering to a subject an immunostimulatory amount of a composition as claimed in claim 9.

### Claim 14 (depends on 5)

A method of preparing an immunotherapeutic agent against S. aureus infection, comprising steps of immunizing subjects with a composition according to claim 5, collecting plasma from said immunized subjects, and harvesting antibodies directed against S. aureus from said collected plasma.

### Claim 15 (depends on 9)

A method of preparing an immunotherapeutic agent against S. aureus infection, comprising steps of immunizing subjects with a composition according to claim 9, collecting plasma from said immunized subjects, and harvesting antibodies directed against S. aureus from said collected plasma.

### Claim 16 (depends on 1)

A composition containing antibodies directed against S. aureus Type 5 polysaccharide antigen, S. aureus Type 8 polysaccharide antigen, and an antigen as claimed in claim 1.

### Claim 17 (depends on 1)

A hyperimmune globulin containing antibodies directed against S. aureus Type 5 polysaccharide antigen, S. aureus Type 8 polysaccharide antigen, and an antigen as claimed in claim 1.

### Claim 18 (depends on 1)

A composition containing a monoclonal antibody directed against S. aureus Type 5 polysaccharide antigen, a monoclonal antibody directed against S. aureus Type 8 polysaccharide antigen, and a monoclonal antibody directed against an antigen as claimed in claim 1.

### Claim 19 (depends on 16)

An immunotherapy method comprising a step of administering to a subject the isolated antibodies as claimed in claim 16.

### Claim 20 (depends on 17)

An immunotherapy method comprising a step of administering to a subject the isolated antibodies as claimed in claim 17.

### Claim 21 (depends on 1)

A monoclonal antibody to the antigen of claim 1.

### Claim 22 (depends on 21)

A composition comprising (a) a monoclonal antibody as claimed in claim 21, (b) at least one of a monoclonal antibody to S. aureus Type 5 polysaccharide antigen and a monoclonal antibody to S. aureus Type 8 polysaccharide antigen, and (c) a sterile, pharmaceutically-acceptable carrier therefor.

### Claim 23 (depends on 22)

A composition as claimed in claim 22, comprising a monoclonal antibody to S. aureus Type 5 polysaccharide antigen and a monoclonal antibody to S. aureus Type 8 polysaccharide antigen.